Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com

Headquarters: Sydney, Australia
Company type: Public company
Number of employees: 50–54
Industry: Pharmaceuticals

Last updated October 28

Latest news about Immutep

In short: Immutep presented EFTISARC-NEO quality-of-life data at ESMO 2026, reported FY2026 results, and advanced its efti pipeline.

Company announcements

October 28 Immutep

Immutep outlines Q1 FY27 clinical and financial updates

The company focuses efti development on HNSCC and STS while advancing IMP761 for autoimmune diseases, securing R&D rebates and maintaining a cash runway into CY28.

September 21 Immutep

Immutep changes ADS ratio to regain Nasdaq compliance

The company adjusts the ratio from 1:10 to 1:200 to meet the $1 minimum bid price requirement effective September 28, 2026.

September 11 Immutep

Immutep outlines focused development strategy for eftilagimod alfa

Immutep targets head and neck cancer and soft tissue sarcoma following TACTI-004 discontinuation. Manufacturing runs will resume at 200 L scale to address analytical differences.

July 30 Immutep

Immutep releases Q4 FY26 quarterly activities report

Efti trials show 7.7-month OS benefit, IMP761 Phase I positive, TACTI-004 futility analysis ongoing, cash at A$68.87M.

Media coverage

September 21 MarketScreener

Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares

Jul. 14 Immutep Granted New US Patent for Cancer Treatment Methods MT Jul. 13 Immutep Receives New US Patent for Cancer Treatment Method; Shares Down...

September 20 MarketScreener

Immutep Limited(ASX:IMM) dropped from S&P/ASX All Ordinaries Index

Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on...

September 10 BioSpace

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) - BioSpace

SYDNEY, AUSTRALIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today...

September 10 Zone Bourse

Immutep: analysis of root causes reveals structural differences in the drug candidate used in the interrupted trial

Immutep has conducted a root cause analysis covering the clinical, pharmacological and manufacturing aspects of its drug candidate eftilagimod alpha, or efti. According to...

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Immutep competitors & trending companies

Browse news for competitors to Immutep and other trending companies.